Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers - Full Text View

Purpose

The aim of the study is a medico-economic evaluation to estimate a cost differential between three modalities of Intensity-Modulated Radiation Therapy for cancers of the prostate, cervix and anal canal with pelvic lymph node irradiation : treatment with helical Tomotherapy and dynamic arc therapy using two different technologies: RapidArc or VMAT.

Condition	Intervention
Prostate Cancer Cervical Cancer Anal Canal Cancers	Radiation: Intensity-Modulated Radiation Therapy

Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: Open Label
Official Title:	Medico-economic Evaluation Comparing Conformal Radiotherapy With Intensity Modulation (IMRT) Performed by, Helical Tomotherapy (Hi Art) and Dynamic Arc Therapy (RapidArc, VMAT) in Cancers With Pelvic Lymph Node Irradiation (Prostate, Cervix, Anal Canal)

Resource links provided by NLM:

MedlinePlus related topics: Cancer Cervical Cancer Prostate Cancer

U.S. FDA Resources

Further study details as provided by Centre René Gauducheau:

Primary Outcome Measures:

Medico-economic study : medical cost differential between 3 ways of Radiotherapy by IMRT (helical tomotherapy and dynamic arc therapy : RapidArc and VMAT). [ Time Frame: 2 months ] [ Designated as safety issue: No ]
Costs of the devices, maintenance costs ; personnel costs directly related to the medical therapeutic procedure (physicians, medical physicists, dosimetry, technicians).

Secondary Outcome Measures:

Others economic criteria [ Time Frame: 2 months ] [ Designated as safety issue: No ]
- the estimation of the cost differential by individualizing the preparation phase and phase radiation
- the analysis of the possible impact of learning in helical tomotherapy and dynamic arc therapy with VMAT and RapidArc measured on direct costs (depending on the age of implantation and equipment)
clinical response and safety of the treatment by radiotherapy [ Time Frame: 18 Months (cervix and canal anal) or 36 months (prostate) ] [ Designated as safety issue: Yes ]
- Assess the skin and mucosal toxicity (acute, delayed) : CTCAEv3
- Assess the prognostic factors of onset of toxicity
- Assess oncological results

Estimated Enrollment:	120
Study Start Date:	March 2011
Estimated Primary Completion Date:	March 2015 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

WHO performance index ≤ 2
Age > 18 years
histologically proven carcinoma: Anal canal cancer locally advanced (> 4 cm and / or N1 to N3) under irradiation on pelvic and inguinal lymph nodes with concurrent chemotherapy. The boost with brachytherapy are accepted Prostate cancer with pelvic lymph nodes and radiation or hormone therapy Cervical Cancer under a purely medical treatment involving irradiation on pelvic lymph nodes and primary tumor with concurrent chemotherapy without surgery. The Boost by external radiotherapy or brachytherapy are accepted.
The investigator must ensure that the patient has not expressed its opposition to participate in this study. The signing of a consent form is optional;

Exclusion Criteria:

History of invasive cancer other than basal cell carcinomas.
Indication of re-irradiation
para-aortic radiotherapy associated with pelvic irradiation.
post-operative radiotherapy.
geographical distance

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01325961

Locations

France
Institut Sainte Catherine	Not yet recruiting
Avignon, France, 84000
Contact: Nicolas Pourel, MD
Principal Investigator: Nicolas Pourel, MD
Sub-Investigator: Bruno Chauvet, MD
Sub-Investigator: Mineur Laurent, MD
Sub-Investigator: Gaëtan de RAuglaudre, MD
Institut Bergonié	Not yet recruiting
Bordeaux, France, 33000
Contact: Guy Kantor, MD
Principal Investigator: Guy Kantor, MD
Centre Léon Bérard	Not yet recruiting
Lyon, France, 69373
Contact: Pascal Pommier, MD
Principal Investigator: Pascal Pommier, MD
Institut Paoli Calmette	Not yet recruiting
Marseille, France, 13273
Contact: Michel Resbeut, MD
Principal Investigator: Michel Resbeut, MD
Sub-Investigator: Mathieu Minsat, MD
Sub-Investigator: Laurence Moureau- Zabotto, MD
Sub-Investigator: Agnes Richard- Tallet, MD
Sub-Investigator: Naji Salem, MD
Sub-Investigator: Gonzague Casabianca, MD
Assistance publique des Hôpitaux de Marseille	Not yet recruiting
Marseille, France, 13385
Contact: Didier Cowen, MD
Principal Investigator: Didier Cowen, MD
Hôpital Clinique Claude Bernard	Not yet recruiting
Metz, France, 57 070
Contact: Guillaume Faure, MD
Principal Investigator: Guillaume Faure, MD
Groupe Oncorad	Not yet recruiting
Montauban, France, 82000
Contact: Philippe Dudouet, MD
Principal Investigator: dudouet Dudouet, MD
Sub-Investigator: Igor Latorzeff, MD
Centre Val d'Aurelle	Not yet recruiting
Montpellier, France, 34298
Contact: David Azria, MD
Principal Investigator: David Azria, MD
Sub-Investigator: Christine Kerr, MD
Centre Alexis Vautrin	Not yet recruiting
Nancy, France, 54500
Contact: Didier Peiffert, MD
Principal Investigator: Didier Peiffert, MD
Sub-Investigator: Véronique Beckendorf, MD
Sub-Investigator: Claire Brunaud, MD
Institut Curie	Not yet recruiting
Paris, France, 75013
Contact: Campitelli, MD
Principal Investigator: Campitelli, MD
Sub-Investigator: De LA ROCHEFORDIERE., MD
Hôpital Européen Georges Pompidou	Not yet recruiting
Paris, France, 75015
Contact: Philippe Giraud, MD
Principal Investigator: Philippe Giraud, MD
Sub-Investigator: Martin Housset, MD
Sub-Investigator: Catherine Durdux, MD
Centre René Gauducheau	Recruiting
Saint Herblain, France
Contact: Marc-André Mahé ma-mahe@nantes.fnclcc.fr
Centre Paul Strauss	Not yet recruiting
Strasbourg, France, 67065
Contact: Georges Noel, MD
Sub-Investigator: Christian Borel, MD
Sub-Investigator: Marius Pop, MD
Institut Claudius Regaud	Not yet recruiting
Toulouse, France, 31000
Contact: Jean-Marc Bachaud, MD
Principal Investigator: Jean-Marc Bachaud, MD
Sub-Investigator: Martine Delannes, MD
Groupe Oncorad	Not yet recruiting
Toulouse, France, 31300
Contact: Denis Franck, MD
Principal Investigator: Denis Franck, MD
Sub-Investigator: Igor Latorzeff, MD
Sub-Investigator: Philippe Dudouet, MD

Sponsors and Collaborators

Centre René Gauducheau

More Information

No publications provided

Responsible Party:	Mme Scotet-Cérato,, Centre René Gauducheau
ClinicalTrials.gov Identifier:	NCT01325961 History of Changes
Other Study ID Numbers:	BRD 10/12-O
Study First Received:	March 28, 2011
Last Updated:	March 29, 2011
Health Authority:	France : French Health Products Safety Agency (AFSSAPS)

Keywords provided by Centre René Gauducheau:

prostate, cervical and anal canal cancers with pelvic lymph node irradiation

Additional relevant MeSH terms:

Uterine Cervical Neoplasms
Prostatic Neoplasms
Anus Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Genital Neoplasms, Male

Genital Diseases, Male
Prostatic Diseases
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Anus Diseases
Rectal Diseases

ClinicalTrials.gov processed this record on May 23, 2013